Johnson & Johnson (JNJ) Stock
NYSEJNJ has an Alpha Score of 52 out of 100 (weak), computed on Oct 28, 2026 from 3 of 4 sub-scores. 70 members of Congress disclosed 242 trades in JNJ since 2014: 142 purchases and 100 sales, most recently Lloyd Doggett (purchase, Sep 8, 2026). 6 of the hedge funds AlphaScala tracks reported JNJ in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Marshall Wace's at $759.25M. Company insiders reported 0 open-market buys and 9 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 38.2 and its net margin 16.2% (key statistics as of Oct 22, 2026).
What is JNJ's Alpha Score?
How it works →Alpha Score of 52 reflects moderate overall profile with strong momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 28, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Johnson & Johnson (JNJ)?
Most recent: Lloyd Doggett (purchase, Sep 8, 2026); records start Jul 23, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lloyd Doggett D-TX · House | 2026-09-08 | purchase | $1k – $15k |
| Tom Kean Jr. R-NJ · House | 2026-08-27 | partial sale | $1k – $15k |
| John Boozman R-AR · Senate | 2026-08-20 | partial sale | $1k – $15k |
| Rich McCormick R-GA · House | 2026-07-30 | sale | $1k – $15k |
| Tom Kean Jr. R-NJ · House | 2026-06-29 | partial sale | $1k – $15k |
| Lloyd Doggett D-TX · House | 2026-06-09 | purchase | $1k – $15k |
| Tom Kean Jr. R-NJ · House | 2026-06-02 | partial sale | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-30 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded JNJ, with filing lags →Which hedge funds own JNJ?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Marshall Wace | 2.99M | $759.25M | +26% |
| Citadel Ken Griffin | 1.50M | $381.17M | -22% |
| D.E. Shaw David Shaw | 687K | $174.54M | -10% |
| Bridgewater Associates Ray Dalio | 669K | $169.94M | -4% |
| Millennium Management Israel Englander | 594K | $150.88M | +3% |
| Soros Fund Management George Soros (founder) | 34K | $8.64M | -2% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Johnson & Johnson insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 2, 26 | Schmid Timothy | EVP, WW Chair, MedTech | SELL | 11.1K | $3.0M |
| Sep 2, 26 | Schmid Timothy | EVP, WW Chair, MedTech | SELL | 22.5K | $6.2M |
| Aug 17, 26 | Taubert Jennifer L | EVP, WWC. Innovative Medicine | SELL | 15.0K | $4.0M |
| Aug 13, 26 | Duato Joaquin | CEO and Chairman of the Board | SELL | 21.0K | $5.5M |
| Aug 13, 26 | Duato Joaquin | CEO and Chairman of the Board | SELL | 102.3K | $26.7M |
| Aug 6, 26 | Forminard Elizabeth | EVP, Chief Legal Officer | SELL | 9.3K | $2.4M |
| Aug 6, 26 | Forminard Elizabeth | EVP, Chief Legal Officer | SELL | 6.6K | $1.7M |
| Aug 5, 26 | Duato Joaquin | CEO and Chairman of the Board | SELL | 42.0K | $10.8M |
| Aug 5, 26 | Duato Joaquin | CEO and Chairman of the Board | SELL | 6.5K | $1.7M |
| Feb 27, 26 | Decker Robert J | VP Corporate Controller | SELL | 4.1K | $1.0M |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are JNJ's key statistics?
Key statistics as of Oct 22, 2026
How does JNJ's valuation compare with the Healthcare sector?
| Metric | JNJ | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 38.2 | 27.1 | 97 |
| Net margin | 16.20% | 5.48% | 139 |
| Return on equity | 25.74% | 6.84% | 158 |
| Dividend yield (payers) | 3.12% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
What did Johnson & Johnson's latest SEC filings say?
Latest 1Johnson and Johnson Announces First Quarter 2026 Financial Results and Dividend Increase
On April 14, 2026, Johnson and Johnson filed an 8-K report to disclose its financial performance for the first quarter ended March 29, 2026. The filing serves as the formal notification of the company's quarterly earnings release, which was provided to the public via an attached press release and supplementary financial data. In addition to the quarterly results, the company announced a change in its capital allocation policy regarding shareholder returns. The Board of Directors declared a 3.1 percent increase in the quarterly dividend. The dividend will rise from $1.30 per share to $1.34 per share. This adjustment represents the 64th consecutive year of dividend increases for the company. On an annualized basis, the new dividend rate is $5.36 per share, up from the previous rate of $5.20 per share. The dividend is scheduled for payment on June 9, 2026, to shareholders of record as of the close of business on May 26, 2026. The ex-dividend date is set for May 26, 2026. The filing includes the condensed consolidated statement of earnings and supplementary sales data for the first quarter of 2026.
- ›Reported financial results for the first quarter ended March 29, 2026.
- ›Increased quarterly dividend by 3.1 percent from $1.30 to $1.34 per share.
- ›Marked the 64th consecutive year of dividend increases.
- ›Established June 9, 2026, as the payment date for the increased dividend.
- ›Set May 26, 2026, as the record date and ex-dividend date for the upcoming payment.
AlphaScala analysis on JNJ
Latest 1JNJ price chart
Powered by TradingViewWhat does Johnson & Johnson do?
Johnson & Johnson is a holding company engaged in the research, development, manufacture, and sale of healthcare products worldwide. It operates through two primary segments: Innovative Medicine, focusing on pharmaceuticals in oncology, immunology, neuroscience, and other therapeutic areas, and MedTech, encompassing medical devices in cardiovascular, orthopaedics, vision care, and electrophysiology. Key products include DARZALEX for oncology, TREMFYA for immunology, and innovative platforms like OMNYPULSE for pulsed-field ablation treatments. Founded in 1887 and headquartered in New Brunswick, New Jersey, the company employs approximately 139,800 people and generates substantial revenue, reaching $94.2 billion in the latest full year with operational growth of 5.3%, driven by a robust pipeline and R&D investments exceeding $32 billion. Johnson & Johnson maintains strong financials, including a dividend yield around 2.1% and consistent payout growth, positioning it as a Dividend King in the healthcare sector. Its diversified portfolio ensures stable cash flows, supporting global distribution through hospitals, physicians, clinics, and partners, while addressing major health challenges across consumer, business, and institutional markets.